This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Hauser, R. G. PubMed PubMed Citation Articles by Hauser, R. G. Related Collections Ablation/ICD/surgery Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2008;118:2117-2119.)
© 2008 American Heart Association, Inc.

Editorial

A Better Method for Preventing Adverse Clinical Events Caused by Implantable Cardioverter-Defibrillator Lead Fractures?

Robert G. Hauser, MD

From the Minneapolis Heart Institute Foundation, Minneapolis, Minn.

Correspondence to Robert G. Hauser, MD, Minneapolis Heart Institute Foundation, 920 E 28th St, Suite 300, Minneapolis, MN 55407. E-mail rhauser747@aol.com

Key Words: Editorials • defibrillation • ICD leads

An extract of the first 250 words of the full text is provided, because this article has no abstract.

In October 2007, the Medtronic Sprint Fidelis implantable cardioverter-defibrillator (ICD) lead was voluntarily withdrawn from the market by the manufacturer because of a higher-than-expected fracture rate.¹ Most Sprint Fidelis fractures involve the pace-sense component of the lead, which may cause oversensing of electrical artifacts, undersensing of ventricular depolarizations, and/or loss of ventricular capture. Approximately 10% to 20% of Sprint Fidelis fractures involve the high-voltage conductor, which may compromise defibrillation. The most common clinical consequence of pace-sense conductor fracture is inappropriate shocks, which often occur in painful clusters and without warning.^2–4 Inappropriate shocks may be proarrhythmic and lethal,^5,6 and patients who experience them may suffer psychological sequelae. ICD lead failures are more likely to result in oversensing than pacemakers because the ICD pulse generators use high-sensitivity amplifiers to effectively detect ventricular fibrillation (VF). In this issue of Circulation, Swerdlow et al⁷ describe a new algorithm that may avoid or reduce inappropriate shocks and other serious adverse events in patients with failed Sprint Fidelis and possibly other high-voltage leads. If this algorithm proves to be safe and effective, it will be an important advance in ICD therapy.

Article p 2122

Fracture of a transvenous high-voltage ICD lead was first observed in the original CPI Endotak model in 1988.⁸ Patients who had this lead suffered multiple inappropriate shocks, and it was withdrawn from clinical trial. Since then, conductor fractures and insulation disruption have challenged engineers and physicians to develop improved designs and implant techniques. Progress has been made, but not without setbacks. . . . [Full Text of this Article]